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Background: To compare the dosimetric effects of Acuros XB (AXB) and Anisotropic Analytical Algorithm (AAA) on
volumetric modulated arc therapy (VMAT) planning for postoperative prostate cancer patients irradiated using an
endorectal balloon (ERB).
Methods: We measured central axis doses with film in a phantom containing an air cavity, and compared
measurements with calculations of the AAA and AXB. For clinical study, 10 patients who had undergone whole
pelvic radiotherapy (WPRT) followed by prostatic bed-only radiotherapy (PBRT) using VMAT were enrolled. An ERB
was used for PBRT but not for WPRT. To compare dosimetric parameters, the cumulative dose-volume histograms,
mean, maximum, and minimum doses were measured for the planning target volume. Homogeneity of plans were
confirmed using V95%, V107% (VX%, percentage volumes receiving at least X% of prescribed doses) and conformity
indices (homogeneity index [HI], conformity index [CI], and conformation number [CN]). We compared volumes of
the organ-at-risk receiving 10% to 100% (10-tier at 10% interval) of prescribed doses (V10% – V100%).
Results: In the phantom study, the AAA showed larger disagreement with the measurements, and overestimated
the dose in the air cavity, comparing with the AXB. For WPRT planning, the AAA predicted a lower maximum dose
and V107% than the AXB. For PBRT planning, the AAA estimated a higher minimum dose, lower maximum dose, and
smaller V107%, and larger V95% than the AXB. Regarding the conformity indices, the AAA was estimated to be more
homogenous than the AXB for PBRT planning (HI, 0.088 vs. 0.120, p = 0.005; CI, 1.052 vs. 1.038, p = 0.022; and CN,
0.920 vs. 0.900, p = 0.007) but not for WPRT planning. Among V10% to V100% of the rectum, the PBRT exhibited
significant discrepancies in V30%, V40%, V70%, V80%, and V90%; while the WPRT did in V20% and V30%.
Conclusions: The phantom study demonstrated that the AXB calculates more accurately in the air cavity than the
AAA. In the clinical setting, the AXB exhibited different dosimetric distributions in the VMAT plans for PBRT
containing an ERB. The AXB should be considered for prostate cancer patients irradiated with an ERB for better
applying of heterogeneous condition.
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After radical prostatectomy, postoperative (adjuvant or
salvage) radiotherapy is recommended for patients with
adverse pathological features or biochemical failure. How-
ever, the extent of radiotherapy—in other words, irradi-
ation of the whole pelvis or prostate bed only—remains
controversial. Although the results of randomized trials
about the extent of radiotherapy have not been reported,
several retrospective studies have shown a benefit of whole
pelvic radiotherapy (WPRT) in terms of biochemical
progression-free survival [1,2]. WPRT encompasses more
pelvic organs than does prostatic bed-only radiotherapy
(PBRT); hence, adverse effects on the genitourinary and
gastrointestinal systems are a primary concern. However,
intensity-modulated radiotherapy (IMRT) can deliver a
higher dose to the target and lower doses to critical organs
[3,4]. Recently, volumetric modulated arc therapy (VMAT),
a next-generation IMRT technique, was introduced. VMAT
has been reported to feature a shorter delivery time and a
plan quality at least comparable to that of fixed-field
IMRT in WPRT [5] and PBRT [6,7].
At our institution, postoperative radiotherapy is per-
formed as follows: WPRT without an ERB followed by
PBRT with an ERB via VMAT. The endorectal balloon
(ERB) was used with its efficiency for prostate cancer
treatment. The use of ERB has been found to be well-
tolerated and effective in reducing the intrafraction
motion and improving the sparing of rectal wall by
reducing the rectal volume in the high-dose region,
resulting in significant reduction in rectal toxicity
[8-12]. However, the ERB is an air cavity and thus ren-
ders the pelvic cavity a heterogeneous area. Tissue het-
erogeneity should be corrected to ensure accurate dose
calculations, especially in small volumes such as the
prostate [13,14].
The Anisotropic Analytical Algorithm (AAA; Varian
Medical Systems, Palo Alto, CA, USA), a commonly
used convolution-superposition algorithm, reflects het-
erogeneity and thus has been proven to provide better
dose calculation results [9,15]. However, the AAA is also
known to overestimate the dose at the air-tumour inter-
face because it incorporates only the density differences
in the heterogeneous media in dose computations [16].
When an ERB is used to reduce the intrafraction mo-
tion, the prostatic bed is located adjacent to the air cav-
ity; therefore, the AAA might yield an inaccurate dose
calculation. Recently, the Acuros XB Advanced Dose
Calculation (AXB) was released in conjunction with the
Eclipse treatment planning system (Varian Medical Sys-
tems). The AXB solves the linear Boltzmann Transport
Equation, and has known similarities to the Monte Carlo
method (MC). In several studies with heterogeneous
media, the AXB has been reported to estimate dose de-
position more accurately than AAA [17-19].To our knowledge, only 1 previous study has com-
pared the dose distributions of AXB and AAA in pros-
tate cancer and found no difference between the results
[20]. However, the above-mentioned study did not used
ERB, so a heterogeneous area created by ERB was not
thoroughly accounted. Therefore, it is needed to com-
pare these differences in more heterogeneous media,
which can result from an ERB. The aim of this study
was to compare the dosimetric impact of AXB and AAA
on VMAT planning for postoperative prostate cancers
treated with an ERB.
Methods
Verification in a phantom with an air cavity
As shown in the Figure 1, a rectangular acryl phantom
with an air cavity was manufactured specially for this
study. The phantom’s overall dimensions were 20 × 20 ×
13.5 cm3, and included an air cavity (10 × 20 × 5 cm3). The
phantom was scanned with the computed tomography
(CT; The Brilliance CT Big Bore, Philips, Netherlands)
simulator. The reconstructed digital imaging and commu-
nication in medicine (DICOM) CT data were then trans-
ferred to the Eclipse. The central axis dose (CAD) was
calculated from AXB and AAA for 5 × 5 cm2 fields of 6
and 10 MV beams. All dose calculations were performed
to deliver 2 Gy to the isocenter at depth of maximum
dose. To evaluate the accuracy of the AXB and AAA, the
CADs were measured by using radiochromic films (Gaf-
Chromic EBT3, International Specialty Products, NJ,
USA) at 2 cm depth of homogeneous zone and various
depths (4.5, 5.5, 6.5, 7.5 and 8.5 cm) of air cavity within
the phantom. The measured CADs were then compared
with the calculations from AXB and AAA. For film dosim-
etry, a calibration curve of film was obtained at the dose
levels from 0 to 5 Gy. The check of linear accelerator out-
put was performed with ion chamber by applying the TG
51 protocol [21].
Patient selection and simulation
Ten prostate cancer patients who had undergone radical
prostatectomy between October 2013 and May 2014
were enrolled in the current planning study, which was
approved by our institutional review board. All patients
were treated with WPRT followed by PBRT. A CT simu-
lation was performed while the patients were placed in a
knee-feet fix (CIVCO, Orange City, IA, USA) in a supine
position on a flat couch. The patients were asked to
drink 300 ml of water 1 hour prior to the simulations
for both WPRT and PBRT to ensure that the bladder
was completely filled. For the PBRT simulation, an ERB
manufactured in our institution (Additional file 1: Figure S1)
was inserted into the rectum and filled with 70 cc of air.
After 1 minute, the ERB catheter was placed at the pre-
marked position, and the inflated ERB was immobilized
Figure 1 Geometric diagram of (A) the phantom with an air cavity and (B) experimental setup for calculation and measurement of the
central axis dose.
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tem was reported in our previous study [12].Table 1 Dose volume constraints adopted for planning
studyTarget delineation
For WPRT, the prostatic bed and regional lymph node
area, including the presacral, obturator, and external and
internal iliac lymph nodes, were contoured as the clin-
ical target volume (CTV). The planning target volume
(PTV) included the CTV plus an additional margin of
0.5 cm in all directions, except the superior and inferior
directions, where a 1-cm margin was added. For PBRT,
only the prostatic bed was delineated as the CTV, and
the PTV was defined as the CTV plus a 1-cm margin in
all directions except posterior to the prostatic bed, where
a 0.7-cm margin was added. The rectum and bladder
were contoured as the organs at risk (OARs). The rec-
tum was contoured to extend from the sigmoid flexure
to the bottom of the ischium.Radiotherapy Organs at risk Constraints
Whole pelvis (44 Gy/22 fractions) Rectum V33 Gy < 50%
V39.6 Gy < 30%
V44 Gy < 20%
Bladder V30.8 Gy < 70%
V39.6 Gy < 50%
V44 Gy < 30%
Prostatic bed (22 Gy/11 fractions) Rectum V11 Gy < 40%
V15.4 Gy < 25%
V19.8 Gy < 10%
Bladder V11 Gy < 35%
V15.4 Gy < 25%
V19.8 Gy < 20%Treatment planning and dosimetric parameter evaluation
Eclipse version 11.0.34 (Varian Medical Systems) was
used to generate the VMAT plans using 10-MV photon
beams from a Varian TrueBeam STx equipped with a
high-definition 120-multileaf collimator in the dynamic
mode at 600 monitor units (MU)/minute. For WPRT,
we used 2 rotating full arcs: the first arc rotated clock-
wise from 181 to 179 degrees with a 30-degree collimator
rotation and the second arc rotated counter-clockwise
from 179 to 181 degrees with a 330-degree collimator ro-
tation. For PBRT, 2 full arcs were used in the same direc-
tions; the degrees of collimator rotation were 15 and 345
for the clockwise and counter-clockwise directions, re-
spectively. The isocenter was the center of the PTVs.The prescription doses were 44 Gy for WPRT followed
by 22 Gy for PBRT, administered in daily doses of 2 Gy.
The goal of optimization was to ensure that ≥95% of the
PTV should receive 100% of the prescribed dose and
that 107% of the prescribed dose should be restricted to
≤5% of the PTV. The dose constraints of the OARs are
listed in Table 1. All VMAT plans were calculated using
both the AAA and AXB algorithms. Two dose-reporting
modes are available in the AXB: dose-to-water (Dw) and
dose-to-medium (Dm); the latter mode was selected. For
the AXB, version 11.0 of the physics material table was
used. For all plans, the optimization was an automatic
intermediate dose calculation. The dose calculation grid
size was set at 2.5 mm for all cases.
Cumulative dose-volume histograms (DVH) and pa-
rameters were calculated for all cases. The average DVH
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averaging the data over the 10 analyzed cases. The mean
doses, maximum doses, and minimum doses to the PTV
were measured. To represent the target coverage and
hot areas, the PTV receiving more than 95% (V95%) and
107% (V107%) of the prescribed dose were evaluated. Sev-
eral conformity indices were analysed to evaluate plan
homogeneity.
First, the homogeneity index (HI) of the PTV (as de-
fined by the International Commission on Radiation
Units and Measurements, report 83 [22]) was calculated
using Equation (1).
HI ¼ D2% −D98%ð Þ
D50%
ð1Þ
D2% represents the maximum dose received by 2% of
the PTV, D98% represents the minimum dose received by
98% of the PTV, and D50% represents the dose received
by 50% of the PTV. A lower HI indicates a more homo-
geneous plan because D2% and D98% are surrogate
markers of the maximum and minimum doses to the
PTV, respectively.
Second, the conformity index (CI) as defined by the





VRI is the volume of reference isodose, and TV is the
PTV volume. A CI equal to 1 corresponds to an ideal
conformation, whereas a CI >1 indicates the irradiation
of healthy tissues [23].
Lastly, the conformation number (CN) was evaluated
to consider the irradiation of healthy tissue. The CN is






TV and TVRI represent the PTV volume and the vol-
ume covered by the reference isodose line, respectively.
The first fraction indicates the quality of target coverage
and the second fraction represents the volume of healthy
tissue irradiated with the reference isodose or higher
[24]. In the present study, we used the 95% isodose as
the reference isodose.
The mean doses, maximum doses, and minimum
doses to the OARs were recorded. We compared vol-
umes of the OAR receiving categorized doses, which the
prescribed dose was divided into 10 ranges at 10% inter-
vals, from V10% to V100%. Additionally, DVHs of OARs
were plotted.
Furthermore, differences of total MUs between the 2
dose calculation algorithms were compared. The Eclipsetreatment planning system was used in this study, includ-
ing both the AXB and AAA algorithms. It was installed on
a standard clinical workstation (Dell® Precision T5500)
with dual 2.4-GHz quad-core Intel processors E5620, 24-
GB RAM memory, and a 64-bit Windows 7 operating
system.
The Wilcoxon rank test was used to evaluate the stat-
istical significance of differences between the AAA and
AXB. Differences were considered to be statistically sig-
nificant at a p-value <0.05. All statistical tests were per-
formed using Predictive Analytics Software, version 18.0
(SAP America, Inc., Newtown Square, PA, USA).
Results
Verification of the central axis dose in the phantom with
an air cavity
The CAD curves for 5 × 5 cm2 field incident on the
phantom with air cavity are shown in Figure 2, for 6 and
10 MV. The percentage differences of calculated CAD
for both algorithms, relative to the film measurements,
are displayed in the same figure at depths of 2, 4.5, 5.5,
6.5, 7.5, and 8.5 cm.
For 6 and 10 MV, The percentage differences of CAD
calculated by both algorithms in homogeneous region
(enlarged circles in Figure 2) were within 1.0% relative
to CAD by film measurement. Excellent agreement was
found between measurement and both algorithms. Al-
though taking little underestimation in air cavity, the
CAD by AXB was found to be in agreement with film
measurement, whereas the AAA results showed higher
CAD to this region compared to the measurements. The
AAA overestimated the dose up to 102.7% for 6 MV and
99.6% for 10 MV. Similar trend were observed in region
of an air-tissue interface. Overall, for AXB, the difference
between the measured and calculated CAD ranged from
−0.3% to 10.9% for 6 MV and from −0.6% to 8.9% for 10
MV. The AAA had wider range of difference between
calculation and measurements, from −0.4% to 102.7%
for 6 MV and from −0.6% to 111.3% for 10 MV.
DVH analysis for the PTV
The mean volumes of the PTVs were 780.87 ± 90.55 cm3
and 160.64 ± 34.05 cm3 for WPRT and PBRT, respect-
ively. The isodose curves for the applied AAA and AXB
plans are presented in Figure 3. The detailed dosimetric
parameters are listed in Table 2. For the WPRT plans, a
small but significant difference was observed in the max-
imum doses to the PTV; specifically, the AAA dose was
lower than the AXB dose (4742.09 cGy vs. 4792.10 cGy,
p = 0.005). The minimum dose was higher with the
AAA, but this difference was not statistically significant
(3330.66 cGy vs. 3259.04 cGy, p = 0.285). V107%, repre-
senting the volume with higher dose, was significantly
smaller with the AAA than with the AXB (0.01% vs.
Figure 2 The central axis depth dose curves calculated by AAA and AXB compared to the measured data using film for 5 × 5 cm2
fields of (A) 6 MV and (B) 10 MV beams; the percentage differences between calculations and measurements for (C) 6 MV and
(D) 10 MV beams at depths of 2, 4.5, 5.5, 6.5, 7.5, and 8.5 cm.
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was observed between AAA and AXB (97.77% and
97.78%, p = 0.878). The average DVH of the PTV for the
AAA and AXB plans is plotted in Figure 4A, which
shows similar curves for WPRT.
For the PBRT plans, the AAA estimated an 11% higher
minimum dose (1887.38 cGy vs. 1687.91 cGy, p = 0.005)
as well as a 1% lower maximum dose (2377.51 cGy vs.
2399.08 cGy, p = 0.028). Additionally, the V107% and V95%
differed significantly between the plans; specifically, the
AAA yielded a smaller V107% (0.04% vs. 0.13%, p = 0.005)
and larger V95% (98.40% vs. 96.62%, p = 0.005) relative to
the AXB. The AAA and AXB curves showed obvious dif-
ference around V95% for PBRT planning (Figure 4B).
Conformity indices for the PTV
For WPRT, no difference was found in the conformity
indices between AAA and AXB. However, for PBRT, all
of the conformity indices were significantly different.
The AAA yielded a lower HI (0.088 vs. 0.120, p = 0.005)
and higher CI (1.053 vs. 1.038, p = 0.022) relative to the
AXB. Similarly, the CN was higher with the AAA. When
the first and second factors were calculated separately,
the first factor was found to be the main contributor to
the difference in the CN (0.984 and 0.966 for AAA andAXB, respectively, p = 0.005), whereas the second factor
was similar for the AAA and AXB (0.935 and 0.932, re-
spectively, p = 0.241).
DVH analysis for the OARs
The mean doses, maximum doses, and minimum doses
to the OARs are listed in Table 3. The maximum and
minimum doses to the rectum exhibited the most signifi-
cant differences between the AAA and AXB, regardless of
the radiation field size. The average DVHs were quantified
as V10% to V100% of the OARs (Table 3) and plotted in
Figure 5. For the rectum, statistically significant discrepan-
cies were found more in PBRT (V30%, V40%, V70%, V80%,
and V90%) than WPRT (V20% and V30%; Figure 5D).
Technical parameters
The percentage differences in the MUs for the prostate
VMAT plans calculated with the 2 algorithms are listed
in Table 4. The average percentage differences in the
total MU between the 2 dose calculation algorithms
were 0.19% for WPRT and 3.54% for PBRT.
Discussion
The AAA accounts for tissue inhomogeneity by independ-
ently assuming the primary beam direction and lateral
Figure 3 Isodose curves for the applied anisotropic analytical algorithm and Acuros XB plans in patients from (A) whole pelvic
radiotherapy and (B) prostatic bed-only radiotherapy.
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considered. Tissue properties are not included in the
AAA, either. In contrast, the AXB considers the move-
ment and interactions of radiation within the heteroge-
neous media and calculates the doses to each voxel
according to the tissue properties. Hence, the AXB can
more accurately predict dose distribution, compared with
the AAA [25,26].
Rana et al. [20] used Rapid Arc plans to perform a plan-
ning study of prostate cancer patients in which the clinical
dosimetric impacts of AAA and AXB were compared. In
that study, the AAA predicted higher minimum and max-
imum doses to the PTV (range, 0.05–0.43%) than did the
AXB, although this difference was not statistically signifi-
cant. Similarly, the V100 (the percentage of PTV covered
by 100% of the prescribed dose) values obtained with
AAA (95%) and AXB (range, 93.1–97.9%) did not signifi-
cantly differ. Although statistical significance was not eval-
uated, the AAA predicted higher doses to the majority ofpoints (average, 94%) in a point-dose difference analysis.
The authors concluded that there were no significant dif-
ferences between AAA and AXB.
In contrast, according to our DVH analysis for PBRT,
the AAA yielded significantly different dose predictions;
in particular, the minimum dose was higher and the
maximum dose lower than those obtained with the AXB.
Similarly, for WPRT, the AAA yielded a lower maximum
dose and tended to predict a higher minimum dose. The
V107% values, or so-called hot spots, were larger when cal-
culated using the AXB for both the WPRT and PBRT
plans. Another dose-volume parameter, the V95% value,
was larger with AAA for the PBRT plans; however, the
values were similar for the WPRT plans. These differences
in the dose-volume parameters might indicate differences
in the target coverage predictions of AAA and AXB.
To compare PTV coverage in greater detail, we ana-
lysed several conformity indices. For the WPRT plans,
the AAA and AXB did not significantly differ with
Table 2 Target coverage, homogeneity, and conformity indices of the planning target volume
Whole pelvic radiotherapy Prostatic bed-only radiotherapy
AAA AXB p AAA AXB p
Maximum Dose (cGy) 4742.09 ± 22.80 4792.10 ± 19.04 0.005 2377.51 ± 17.18 2399.08 ± 14.92 0.028
Minimum Dose (cGy) 3330.66 ± 226.58 3259.04 ± 226.00 0.285 1887.38 ± 133.54 1687.91 ± 218.88 0.005
Mean Dose (cGy) 4465.49 ± 13.67 4463.18 ± 11.16 0.037 2233.12 ± 8.17 2230.54 ± 7.94 0.333
95% Isodose Volume (cm3) 819.53 ± 128.25 820.56 ± 128.71 0.037 168.96 ± 35.32 166.83 ± 36.14 0.022
V107% (%) 0.01 ± 0.01 0.03 ± 0.02 0.005 0.04 ± 0.04 0.13 ± 0.10 0.005
V100% (%) 81.81 ± 3.00 81.08 ± 2.82 0.013 83.19 ± 4.34 83.85 ± 2.44 0.959
V95% (%) 97.77 ± 0.43 97.76 ± 0.49 0.878 98.40 ± 0.76 96.62 ± 1.10 0.005
D2% (%) 104.75 ± 0.44 104.88 ± 0.36 0.017 104.42 ± 0.38 104.69 ± 0.33 0.161
D98% (%) 94.86 ± 0.50 94.86 ± 0.59 0.859 95.49 ± 0.83 92.46 ± 1.92 0.005
Homogeneity Index 0.097 ± 0.007 0.098 ± 0.008 0.059 0.088 ± 0.007 0.120 ± 0.019 0.005
Conformity Index 1.047 ± 0.071 1.048 ± 0.071 0.059 1.053 ± 0.041 1.038 ± 0.031 0.022
Conformation Number 0.916 ± 0.049 0.915 ± 0.049 0.203 0.920 ± 0.026 0.900 ± 0.028 0.007
First Factor 0.978 ± 0.004 0.978 ± 0.005 0.878 0.984 ± 0.008 0.966 ± 0.011 0.005
Second Factor 0.937 ± 0.052 0.936 ± 0.052 0.074 0.935 ± 0.030 0.932 ± 0.026 0.241
AAA = Anisotropic Analytical Algorithm; AXB = Acuros XB.
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PBRT plans, we observed significant differences in the
conformity indices. First, the HI values were lower with
the AAA than with the AXB. A lower HI value indicates
more homogeneous target coverage, and therefore, the
AAA could be expected to underestimate heterogeneity
in the PBRT plans. Second, the AAA was found to have
a higher CI value, indicating that the V95% in the PBRT
plans was overestimated by the AAA. Third, a discrep-
ancy was found in the CN values, particularly in the first
part of the equation, which defines the quality of target
coverage. Therefore, conformity indices analysed in the
current study implied that heterogeneity of the PBRT
fields was less reflected by the AAA than the AXB.Figure 4 The cumulative dose-volume histograms of the planning tar
plans averaged over the 10 analysed patient’s plans for (A) the wholeIn the PBRT plans, the dosimetric discrepancies be-
tween the AAA and AXB were likely influenced by the
ERB. Because the ERB generates an air cavity in the rec-
tum, the resulting heterogeneity should be corrected in
order to accurately predict the dose distribution in the
prostatic bed. According to our DVH analysis for the
rectum, the AAA and AXB exhibited significant differ-
ences in 5 ranges in the PBRT plan and in 2 ranges in
the WPRT plan. These discrepancies were confirmed in
the average DVH plots for the rectum (Figure 5D). The
average DVH plots for other OARs did not differ signifi-
cantly between the WPRT and PBRT plans.
Previous studies that compared the clinical impact of
AXB and AAA in patients with non-small cell lung cancerget volumes (PTVs) in the AAA (solid line) and AXB (dotted line)
pelvic radiotherapy and (B) the prostatic bed only radiotherapy.
Table 3 Dosimetric data of organs at risk







V10% (%) V20% (%) V30% (%) V40% (%) V50% (%) V60% (%) V70% (%) V80% (%) V90% (%) V100% (%)
AAA Mean 4747.15 1266.97 3595.53 100.00 99.97 98.59 96.02 90.12 78.44 67.44 58.39 49.97 35.52
(SD) 149.54 403.32 284.69 0.00 0.08 2.62 6.12 7.83 9.52 11.31 12.95 14.26 13.70
AXB Mean 4732.93 1236.55 3585.11 100.00 99.96 98.49 95.71 89.69 77.93 67.11 58.24 49.95 35.48
(SD) 172.23 388.58 287.13 0.00 0.10 2.76 6.13 7.89 9.52 11.31 13.00 14.32 13.71
p 0.114 0.059 0.005 1 0.109 0.138 0.012 0.007 0.005 0.005 0.047 0.959 0.646







V10% (%) V20% (%) V30% (%) V40% (%) V50% (%) V60% (%) V70% (%) V80% (%) V90% (%) V100% (%)
AAA Mean 2365.24 35.61 776.31 53.23 45.04 40.66 36.44 31.78 27.51 23.91 20.98 18.42 14.61
(SD) 21.69 34.74 280.98 17.47 15.81 15.21 14.96 13.98 12.58 11.14 9.94 8.92 7.56
AXB Mean 2377.19 32.77 775.61 52.16 45.01 40.74 36.52 31.84 27.58 24.05 21.19 18.60 14.96
(SD) 32.42 32.39 284.16 17.25 15.85 15.30 15.03 14.04 12.66 11.27 10.10 9.08 7.90
p 0.114 0.005 0.646 0.007 0.093 0.799 0.646 0.508 0.444 0.047 0.007 0.013 0.285







V10% (%) V20% (%) V30% (%) V40% (%) V50% (%) V60% (%) V70% (%) V80% (%) V90% (%) V100% (%)
AAA Mean 4650.79 546.54 2991.27 99.45 95.35 88.80 80.75 70.69 61.36 51.85 41.34 29.25 11.98
(SD) 55.88 178.89 337.26 1.18 4.25 8.93 10.28 11.61 13.17 13.29 11.31 9.51 7.18
AXB Mean 4694.80 516.34 2981.62 99.39 94.36 88.32 80.86 70.96 61.61 51.75 40.53 28.22 12.96
(SD) 58.69 169.66 347.89 1.30 5.22 9.37 10.51 11.76 13.31 13.57 11.91 10.01 7.14
p 0.028 0.013 0.386 0.109 0.007 0.013 0.203 0.575 0.386 0.878 0.508 0.241 0.093







V10% (%) V20% (%) V30% (%) V40% (%) V50% (%) V60% (%) V70% (%) V80% (%) V90% (%) V100% (%)
AAA Mean 2300.09 80.53 1041.95 92.07 83.50 64.17 48.57 39.04 31.64 25.34 19.90 14.54 4.66
(SD) 22.59 35.67 115.34 7.34 10.20 10.26 6.94 5.65 5.77 5.93 5.54 4.59 2.50
AXB Mean 2331.40 76.05 1038.99 92.83 84.35 68.70 52.15 40.24 30.99 23.02 16.03 10.36 4.15
(SD) 30.64 34.04 108.82 5.29 8.07 8.55 7.66 6.66 6.56 6.02 4.68 2.92 1.42
p 0.007 0.005 0.646 0.169 0.799 0.009 0.007 0.093 0.285 0.005 0.005 0.005 0.333











Figure 5 The cumulative dose-volume histograms of the organs at risk in the AAA (solid line) and AXB (dotted line) plans averaged
over the 10 analysed patient’s plans: (A) bladder in the whole pelvic radiotherapy, (B) bladder in the prostatic bed only radiotherapy,
(C) rectum in the whole pelvic radiotherapy, and (D) rectum in the prostatic bed only radiotherapy.
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dose distributions differed beyond the air cavity. In hetero-
geneous phantom studies, the dosimetric result of the
AXB was more similar to MC than to the AAA [17,18,28].
In a heterogeneous interface-containing phantom, some
differences between both algorithms were pointed out at
interface between different materials and the doses calcu-
lated by AXB were significantly lower at the air-tissue
interface than were those calculated by the AAA. Relative
to the MC calculation, the AXB exhibited ±2% agreement,
whereas the AAA exhibited a greater difference of up to
17.5% [18]. In a measurement study with inhomogeneous
phantoms containing air gap, measured data were com-
pared with doses calculated by the AAA and AXB [29].Table 4 The average monitor units between two dose calcula
plans for all patients
Treatment AAA (Av
Whole pelvic radiotherapy Monitor Unit 523 ± 45
Prostatic bed-only radiotherapy Monitor Unit 508 ± 29
AAA = Anisotropic Analytical Algorithm; AXB = Acuros XB; Avg = Average, SD = StandAccording to this study, the AXB showed less discrepan-
cies (−3.81% to + 0.9%) with measured data than the AAA
(−3.1% to − 10.9%). However, in an air cavity, the differ-
ence between measured and calculated data was not men-
tioned in this study.
In our phantom study, film measurements were per-
formed in an air cavity and the air-tissue interface. Our
verification results showed that the calculated results of
AXB had better agreement in air cavity and air-tissue
interface than that of AAA when compared to the mea-
sured data. The results of film measurement, of course,
showed actually little larger than that of AXB. The reason
may be mainly due to film’s property which has the tissue-
equivalent density. We found that dosimetric results intion algorithms on volumetric modulated arc therapy
g ± SD) AXB (Avg ± SD) Relative difference (%)
524 ± 45 0.19
526 ± 33 3.54
ard deviation.
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the inclusion of the dosimeter, leading to an error in dose
estimate. Therefore, care should be taken when perform-
ing measurements with film in phantom containing an air
cavity.
The above-mentioned planning study conducted by
Rana et al. [20], which compared the AAA and AXB in
the context of prostate cancer patients, differed from
our study in several aspects. First, a partial single-arc
technique was used to avoid beam entrance through the
couch-rails. Second, an ERB was not used. Consequently,
it was possible that the heterogeneity due to the air cavity
in the rectum had little influence on dose distribution. In
contrast, we concurrently used 2 full arcs and an ERB;
hence, the AAA and AXB exhibited differences in the pre-
dicted dose distributions. Additionally, Rana et al. [20]
used same number of MUs for AAA and AXB, different
from our study. In particular, the differences in MUs were
more prominent in the PBRT plans, up to 3.54%. Similarly,
Khan et al. [30] reported that the AXB required more
MUs (average 2%) compared with AAA. This can be ex-
plained that more MUs were required by the increase of
heterogeneity region in PTV due to use of an ERB.
In the current study, calculated rectal dose had statisti-
cally significant difference between the AAA and AXB,
but the difference was somewhat small in absolute value.
This may be because we prescribed relatively low dose
for the PBRT planning. With the elevated dose, the ab-
solute difference would be more marked.
Conclusions
Our phantom study demonstrated that the AXB is sig-
nificantly more accurate for dose calculation in the re-
gion of air cavity and air-tissue interface than the AAA,
when compared to the measured data. For comparison
of 10 patients with prostate cancer, the AXB and AAA
yielded significantly different dosimetric distributions for
VMAT plans with 2 full arcs for prostate cancer. In par-
ticular, several conformity indices were significantly differ-
ent for the PBRT plans. These differences likely resulted
from the ERB being used for PBRT, which was located pos-
terior to the prostatic bed and rendered the radiation field
a heterogeneous area. The differences in the dose-volume
parameters for the rectum were remarkable in the PBRT
plans generated with AXB and AAA. The AXB should be
considered rather than the AAA for prostate cancer pa-
tients irradiated with an ERB for better applying of hetero-
geneous condition and precise analysing of rectal dose.
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